Ann Arbor-based Strata Oncology Inc., a precision oncology company advancing molecular indications for cancer therapies, has completed a renovation and expansion of its high-throughput cancer sequencing facility, resulting in a doubling of its previous laboratory capacity.
The lab expansion incorporates technology and operational throughput to deliver StrataNGS, a genomic profiling test with industry-low tumor tissue requirements, to more physicians and their patients. Strata also increased its research and development capacity to continue to expand its portfolio of molecular profiling tests.
Earlier this year, Strata opened a new headquarters facility on the same property in Ann Arbor. The new facility provides flexible space for the company’s growing business, clinical operations, scientific, and software engineering teams.
While most of Strata’s employees continue to work remotely during the COVID-19 pandemic, the facility accommodates workspace design to support the company’s strategy to create an agile post-pandemic workplace.
“Over the past year, we have experienced a 50 percent growth in headcount, including 30 percent growth since the pandemic began in March,” says Dan Rhodes, CEO and co-founder.
“The investment in an expanded cancer diagnostics testing facility and new headquarters reflects our commitment to ensure every patient with advanced cancer receives their best possible treatment and confirms the importance of Ann Arbor as our hub for advancing precision oncology.”
A recent study presented at the 2020 Annual Meeting of the American Society of Clinical Oncology showed that the performance of StrataNGS on small tumor tissue samples may enable access to testing for more than double the number of patients compared to other tests.
StrataNGS is a genomic profiling test that features leading performance on small tumor tissue samples. The 429-gene assay is performed on co-isolated RNA and DNA.
